Companies Dominating the Inflammatory Bowel Disease Treatment Landscape
- The Bristol-Myers Squibb Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bausch Health Companies Inc.
- AbbVie Inc.
- Novartis AG
- UCB Biopharma SRL
- Biogen Inc.
- Pfizer, Inc.
- Janssen Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Celltrion Healthcare Co., Ltd.
The market is evolving with the penetration of technological escalation and rigorous R&D cohorts. Key players in this sector are significantly contributing to this scenario by forming strategic partnerships, global-scale commercialization, and enhanced production. They are continuously developing innovative therapeutics to offer personalized care to every individual. For instance, in October 2023, Pfizer attained clearance from the FDA to market its oral, once-daily, receptor modulator, VELSIPITY (etrasimod). The recommended 2 mg dose of this medicine has been proven to be effective for treating adults with moderately to severely active ulcerative colitis. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of inflammatory bowel disease treatment is estimated at USD 24.53 billion.
The global inflammatory bowel disease treatment market was likely to rise from USD 23.26 billion in 2024 to USD 61.75 billion by 2037, witnessing a CAGR of around 7.8% throughout the forecast period, between 2025 and 2037.
North America industry is set to hold largest revenue share by 2037, impelled by high prevalence and rising incidence of ulcerative colitis and Crohn's disease in the region.
The major players in the market include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB Biopharma SRL, Biogen Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited.
